Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - 3-Month Efficacy Study

NCT01256684
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 20 more
Recruiting Early Phase 1 Interventional

The Effects of Fluoxetine and/or DHEA

NCT03228732
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo Oral Tablet, Fluoxetine, DHEA, Fluoxetine and DHEA
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
HIV Infections
Interventions
DHEA
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
San Francisco, California
Conditions
Lupus
Interventions
Prasterone (GL701)
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more
Conditions
Vaginal Atrophy
Interventions
Placebo, Prasterone (DHEA)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Vaginal Ecosystem and Network in the United States Study

NCT06472765
Conditions
Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions
Vaginal Swab Collection
Diagnostic Test
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
3,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Pasadena, California + 16 more
Conditions
Hypoactive Sexual Desire Disorder (HSDD)
Interventions
Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Huntsville, Alabama • San Diego, California • New London, Connecticut + 7 more
Conditions
Primary Ovarian Insufficiency, Female Infertility Due to Diminished Ovarian Reserve
Interventions
Testosterone cream (0.5mg per gram), DHEA, Placebo
Drug · Dietary Supplement
Lead sponsor
Center for Human Reproduction
Other
Eligibility
38 Years to 44 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
2
States / cities
New York, New York • Rochester, New York
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

DHEA and Testosterone Replacement in Elderly

NCT00254371
Conditions
Aging, Low DHEA for Women, Low Testosterone and DHEA for Men
Interventions
Androgen Replacement
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Vaginal Atrophy
Interventions
DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
31
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 26 more
Conditions
Depressive Disorder, Mood Disorder
Interventions
Dehydroepiandrosterone
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions
Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
Drug · Combination Product
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Systemic Lupus Erythematosus
Interventions
GL701
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Redwood City, California
Conditions
Substance Withdrawal Syndrome
Interventions
dehydroepiandrosterone (DHEA), pregnenolone, Placebo
Dietary Supplement · Drug
Lead sponsor
Jed E. Rose
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Androgen Administration on Inflammation in Normal Women

NCT01753037
Conditions
Hyperandrogenism
Interventions
Dehydroepiandrosterone (DHEA), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Dyspareunia
Interventions
Prasterone
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Diego, California
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Dehydroepiandrosterone (DHEA) in Humans

NCT00182975
Conditions
Aging
Interventions
DHEA replacement
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Mild Cognitive Impairment, Dementia, Mild
Interventions
Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care, Lifestyle including diet, exercise, stress management
Dietary Supplement · Combination Product · Behavioral
Lead sponsor
Alzheimer's Prevention and Reversal Project, Inc.
Other
Eligibility
45 Years to 76 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Folsom, California • San Rafael, California • Walnut Creek, California + 3 more
Conditions
Breast Cancer
Interventions
letrozole, DHEA, pharmacological study
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Breast Cancer
Interventions
polymorphism analysis, high performance liquid chromatography, laboratory biomarker analysis, radiomammography
Genetic · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
180
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 111 more
Completed Not applicable Interventional Accepts healthy volunteers

DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

NCT03227458
Conditions
Low Bone Mass, Osteoporosis, Postmenopausal
Interventions
DHEA, Placebo, Exercise
Other · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado